Webinar List
This series explores innovative approaches to thoracic procedures, highlighting the
evolving discussion around segmentectomy and its benefits. Our expert panel, featuring
five top specialists from the Asia Pacific region, shares their techniques and strategies for
segmentectomy.
In this part, Dr. Shun-Ichi Watanabe’s lecture focused on surgical options for non-small
cell lung cancer, emphasizing that tumor size and CT ratio are crucial in determining the
appropriate surgical approach, particularly for GGO-dominant tumors. Segmentectomy is
effective, especially in elderly or high-risk patients, but requires careful consideration in
younger or female patients due to a higher risk of recurrence. Additionally, lymph node
dissection is recommended for solid tumors due to the risk of lymph node metastasis.
Dr. In Kyu Parks’ lecture focused the intricacies of segmentectomy, particularly for the left
upper lobe. He emphasized that precise patient selection and thorough preoperative
planning are critical for successful outcomes. Key considerations include understanding
arterial variations, achieving sufficient resection margins, and preventing postoperative
dysfunction of the remaining lung. Dr. Park highlighted the importance of lymph node
dissection in managing regional disease and noted that segmentectomy is distinct from
lobectomy, requiring careful technique to optimize patient outcomes.
Dr. Yin-Kai Chao’s lecture focused on the technical aspects of performing left upper lobe
segmentectomy using robotic surgery. He emphasized the importance of thorough
anatomical knowledge and preoperative planning, particularly in understanding segmental
arteries and bronchi. Dr. Chao also highlighted the necessity of extensive lymph node
dissection, which he believes simplifies segmentectomy and lobectomy. He discussed the
use of ICG for identifying intersegmental planes and stressed that effective coordination
with surgical assistants is key for successful robotic segmentectomy.
This series explores innovative approaches to thoracic procedures, highlighting the
evolving discussion around segmentectomy and its benefits. Our expert panel, featuring
five top specialists from the Asia Pacific region, shares their techniques and strategies for
segmentectomy.
In this part, Dr. Shun-Ichi Watanabe summarized the JCOG 0802 trial results, highlighting
that although segmentectomy showed only a slight 3% improvement in overall survival
(OS) compared to lobectomy, it also had a higher local recurrence rate (10% vs. 5%).
Interestingly, non-lung cancer deaths were more frequent in the lobectomy group, though
the cause remains unclear. Segmentectomy patients received more aggressive treatment
for relapses and secondary cancers, possibly contributing to better outcomes in this group.
The pulmonary function difference between the two groups was smaller than expected, at
only 3.5% one year post-surgery.
Dr. Mingyon Mun's presentation emphasizes the importance of detailed anatomical
knowledge when performing right upper lobe segmentectomy, highlighting critical
intersegmental veins (B1, B2, B3) that define surgical boundaries. He underscores the role
of 3D reconstruction and CT scans for preoperative planning to assess tumor size, location,
and anatomical variations. Intraoperatively, bronchoscopy, pulmonary artery exposure, and
techniques such as inflation-deflation lines and ICG fluorescence help confirm segmental
borders. Dr. Mun discusses surgical margin evaluation, particularly in complex resections,
where precise dissection is essential for successful outcomes.
Dr. Agasthian Thirugnanam discusses the management of multiple ground-glass
opacities (GGOs) and the importance of segmentectomy, particularly in patients with
compromised lung function or multiple primary lung cancers. He highlights that earlier lung
cancers often appeared biologically advanced, leading to higher recurrence rates after
segmentectomy. However, the advent of lung cancer screening has enabled earlier
detection of biologically less aggressive cancers, such as GGOs, which have better
outcomes. He emphasizes careful follow-up to differentiate benign GGOs from malignant
ones, advocating for tailored surgical approaches based on radiological and pathological
findings. He also introduce a couple of local treatment other than surgery for NSCLC.
This series explores innovative approaches to thoracic procedures, highlighting the
evolving discussion around segmentectomy and its benefits. Our expert panel, featuring
five top specialists from the Asia Pacific region, shares their techniques and strategies for
segmentectomy.
In this part, Dr. Shun-Ichi Watanabe presented the final results of the JCOG0802 trial
focusing on “Local Recurrence”. This study compared segmentectomy with lobectomy,
finding that while segmentectomy showed superior overall survival, it was associated with a
higher rate of local recurrence. Dr. Watanabe emphasized the need for caution when
performing segmentectomy, particularly in younger female patients, and concluded that
ensuring an adequate surgical margin is crucial.
Dr. Nan Wu presented on the use of an AI-based 3D virtual imaging system in S6
segmentectomy, emphasizing its role in precise surgical planning and navigation. The S6
segment is anatomically complex and requires special attention. The AI system aids in
identifying anatomical differences and ensuring adequate margins to prevent recurrence.
Recurrence rates vary depending on tumor location, with tumors near the mediastinum
leading to N2 lymph node metastasis. S3 tumors have a higher likelihood of causing N2
metastasis by bypassing other segments. If malignant findings are confirmed after surgery,
adjuvant therapy is recommended due to the challenges of reoperation.
Lung cancer is the deadliest cancer worldwide and the most common cancer in Asia. In fact, 59% of all lung cancer cases occurs in Asia and around 21% of all cancer related deaths in Asia are lung cancer-related.
The treatment of lung cancer is evolving rapidly, and current evidences are beginning to show that new approaches for thoracic procedures & treatments have excellent outcomes towards the quality of life.
However, `Lobectomy` is still the fundamental procedure at this moment. Hence, to improve this technique would greatly improve patient outcomes.
In this webinar, three top experts from Asia Pacific shared their technique, strategy and insights for VATS lobectomy from various aspect.
In this webinar, we bring a global perspective that will challenge the current Gold Standard of treatment. Dr. Watanabe from Japan, will share the results of JCOG0802 which have been recently reported on AATS. Dr. Harvey Pass of the U.S. will share the design of CALGB140503, the results of which will be released next year, and Dr. Fang from China, will moderate the discussion following the presentations.
Will these two studies change the future of treatment of lung cancer and challenge the Gold Standard?
In addition, we will have a panel discussion on the strategy for the treatment of early lung cancer, with a broad overview on how these changes might impact patients, surgical care teams and surgical societies. This discussion will be focusing on these new studies, the evidence generated and the experts' views on it.
This session is moderated by Dr. Anand Shastri, Thoracic Surgeon and the Senior Director, Medical and Clinical Affairs for Johnson and Johnson India, and for Ethicon, Asia Pacific.
The medical devices mentioned in this presentation are for illustrative purpose only. Not all products are licensed or available in all Asia Pacific and EMEA countries. This publication is not intended for distribution outside of the Asia Pacific and EMEA region. The third-party trademarks used herein are the trademarks of the respective owners.
213111-220510
販売名：パワードエシェロンフレックス７ 認証番号：227AABZX00087000
販売名：パワードエシェロンフレックス７カートリッジ 承認番号：22700BZX00290000
販売名：ＧＳＴカートリッジ 承認番号：22700BZX00155000
販売名：エンドスコピック パワード リニヤー カッター 認証番号：22500BZX00396000
販売名：バイクリル 承認番号：15700BZY01341000
Lung cancer is the deadliest cancer worldwide and the most common cancer in Asia. In fact, 59% of all lung cancer cases occur in Asia and furthermore, 21% of all cancer related deaths in Asia are because of lung cancer. In addition, approximately one third of all lung cancer patients in East Asia are non-smokers. The treatment of lung cancer is evolving rapidly, and current evidence is beginning to show that new approaches for thoracic procedures and treatments have excellent outcomes and quality of life related results. Advances in diagnostic methods, earlier diagnosis and the important requirement of preserving as much lung function as possible, have made lung cancer surgery evolve to become as Minimally Invasive as possible and hence, has led to the widespread adoption of VATS and Uniportal VATS in Asia. In addition, lung function preserving operations such as segmentectomy and sub lobar radical resections also have a high interest in Asia Pacific and are being adopted as a new procedure strategy.
There are two big studies that are being conducted in Japan (JCOG0802) and in the US(CALGB140503), on the oncological outcomes of VATS segmentectomy and its comparison with the more traditional VATS lobectomy. This is the first episode of our exciting series of two live webinars, where thoracic experts from Asia Pacific will share their clinical experiences, and practical techniques on VATS segmentectomy. This discussion on surgical methods, pros and cons will be underpinned with the latest evidence available.
The medical devices mentioned in this presentation are for illustrative purpose only. Not all products are licensed or available in all Asia Pacific and EMEA countries. This publication is not intended for distribution outside of the Asia Pacific and EMEA region. The third-party trademarks used herein are the trademarks of the respective owners.
213079-220510
販売名：エンドパス エンドカッター ＥＣ４５ 承認番号：22100BZX00089000
販売名：エンドカッター 承認番号：21900BZX00881000
販売名：パワードエシェロンフレックス７ 認証番号：227AABZX00087000
販売名：パワードエシェロンフレックス７カートリッジ 承認番号：22700BZX00290000
販売名：ＧＳＴカートリッジ 承認番号：22700BZX00155000
There is only one straight access from the utility port to the target structure, and this straight access should be reserved for operator's right hand, to ensure the maximum degree of freedom and safety. For any experienced single port surgeon, the best instrument setting will be Harmonic HD1000i in operator’s right hand for sharp dissection, and long curved sucker in operator’s left hand for suction/traction/blunt dissection. Find out more on the key points of the surgical procedure of single port VATS lobectomy with Dr Liu Chia-Chuan.
219859-220706